PT-141 10 mg

Peptide Hubs PT-141 10

Peptide Hubs offers premium, lab-tested PT-141 10 mg, a synthetic peptide analog of α-MSH (alpha-melanocyte-stimulating hormone) known as Bremelanotide. Sourced from a legit Peptide Hubs network, this lyophilized powder is rigorously analyzed to ensure researchers receive a compound of exacting purity and potency for investigating melanocortin receptor pathways. Unlike hormone-based therapies, PT-141 operates through a unique CNS-mediated mechanism, making it a fascinating subject for research into sexual arousal, libido, and related neural circuits.

PT-141 Composition

Each 2 mL glass vial contains 10 mg of high-purity Bremelanotide (PT-141) in a sterile, lyophilized powder form. Our third-party lab analysis confirms a content of 11.78 mg per vial, exceeding the labeled potency and demonstrating our commitment to quality. The peptide sequence (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2) is synthesized without fillers or binders, ensuring precise and consistent research application upon reconstitution.

Bodybuilding Benefits

While not an anabolic agent, PT-141 is of significant research interest in contexts related to athlete wellness and psychological performance. Intense training regimes, caloric deficits, and hormonal cycles can sometimes impact libido and sexual function—a key marker of overall endocrine and psychological health. Research into PT-141 focuses on its potential to modulate sexual desire and arousal through central nervous system pathways independently of the endocrine system. For scientists studying the mind-body connection in high-performance models, PT-141 provides a tool to explore non-hormonal avenues for supporting quality of life and mental well-being, which can indirectly influence training consistency and recovery mindset.

Therapeutic Indication

In clinical and preclinical research, Bremelanotide (PT-141) is primarily investigated for treating hypoactive sexual desire disorder (HSDD) and female sexual arousal disorder (FSAD). Its mechanism is distinct from PDE5 inhibitors; it activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly the hypothalamus, to initiate pro-sexual responses. This makes it a valuable compound for neuroscientific studies on sexual motivation, arousal pathways, and the role of melanocortins in behavior. The U.S. Food and Drug Administration (FDA) has approved a Bremelanotide product (Vyleesi®) for HSDD, underscoring the validated biological activity of this peptide class.

Dosage Men

Research Use Only: The following is derived from published clinical trial data for informational context. Actual research protocols must be designed by qualified professionals. In human clinical studies, subcutaneous doses of Bremelanotide typically ranged from 0.3 mg to 2 mg. Researchers must calculate appropriate doses for their specific in vitro or in vivo models, always adhering to the principle of using the lowest effective dose to answer the research question.

Dosage Women

Clinical research on the approved drug indicates similar dosing parameters for female subjects. The dose-response is highly individualized in human trials. For laboratory research, gender-specific dosing is not typically relevant for initial in vitro studies. In vivo research must follow strict ethical guidelines, and dosage is determined by model physiology, not human equivalency.

Active Life & Pharmacokinetics

Research indicates PT-141 has a relatively short half-life, with effects on sexual arousal in clinical models being observed within a few hours post-administration and lasting for several hours. The window of biological activity in research models is crucial for designing timed observational studies related to behavioral or neurological endpoints.

PT-141 Side Effects

In clinical trial data, the most commonly reported transient effects included flushing, nausea, and transient increases in blood pressure. These are generally mild and self-limiting. In a research setting, potential off-target effects could include minor, short-lived changes in appetite or grooming behaviors in animal models due to melanocortin receptor activity. Proper dosing and administration technique are critical to minimizing adverse events in any research model.

PT-141 Contraindications/Precautionary Measures

Research should not be conducted in models with uncontrolled hypertension or significant cardiovascular disease. It is contraindicated in pregnancy models. Bremelanotide may interact with drugs that affect blood pressure. All handling must occur in a controlled lab environment. Researchers should review safety data and consult guidelines from authoritative sources like the National Institutes of Health (NIH) on safe laboratory practices.

Overdosage

Data on PT-141 overdose is limited. In a research context, significantly exceeding established experimental parameters may amplify side effects such as pronounced nausea, vomiting, or hypertensive response, compromising the welfare of the model and the integrity of the study. Emergency procedures for chemical exposure must be established prior to commencing research.

PT-141 Stack/Cycle

PT-141 is typically researched as a standalone agent for its specific CNS effects. However, researchers may design complex studies to investigate synergistic or modulating effects with other compounds. For example, stacking with libido-modulating peptides like Kisspeptin 10 mg could explore integrated hypothalamic-pituitary-gonadal axis responses. To study overall wellness and metabolic context, researchers might combine it with peptides like Tesamorelin 5 mg (for body composition) or GHRP-6 10 mg (for GH release and recovery). For broader endocrine research frameworks, it could be included in studies with CJC-1295 No DAC 5 mg or Melanotan 2 10 mg (another α-MSH analog). Such stacks require highly controlled, multi-variable experimental designs.

Package Presentation

Your order arrives as one sealed, tamper-evident 2 mL glass vial containing 10 mg of PT-141 as a white lyophilized powder. The label clearly displays the product name, batch number, expiration date, and net weight.

Storage

For maximum stability, store unopened vials in a refrigerator at 2-8°C (36-46°F). Keep away from light and moisture. After reconstitution with sterile bacteriostatic water, the solution should be refrigerated and used within a short timeframe as defined by your laboratory's sterility and stability protocols.

PT-141 Referrers

PT-141 (Bremelanotide) represents a significant advance in peptide research, moving beyond peripheral effects to central nervous system modulation. Its development and FDA approval for HSDD highlight the therapeutic potential of melanocortin receptor agonists. For researchers, Peptide Hubs' PT-141 provides a reliable, verified tool to explore the intricate neurochemistry of sexual behavior, the interplay between neural circuits and peripheral function, and the broader role of melanocortins in physiology and behavior.

Third-Party Lab Test

2025-04-22

View Result

11.78 mg